Please assess the completion status of the following clinical trial:

Trial Title: Combination Chemotherapy and Rituximab in Treating Patients With Newly Diagnosed Primary CNS Lymphoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically confirmed untreated primary CNS lymphoma (PCNSL) confirmed by 1 of the following methods:~  * Brain biopsy or resection~    * Patients diagnosed with T-cell PCNSL allowed but will not receive rituximab on study~ * Cerebrospinal fluid (CSF) cytology~    * Positive CSF cytology with or without measurable intracranial disease~ * Vitreal biopsy~    * Histologic confirmation of vitreal lymphoma with measurable intracranial tumor~* No evidence of systemic non-Hodgkin's lymphoma~  * CT scan of chest, abdomen, and pelvis or bone marrow biopsy negative for extracerebral source of lymphoma~* No evidence of pleural effusions or ascites~* MRI of brain and spine (plus gadolinium) must have measurable contrast enhancing disease unless CSF cytology is positive~PATIENT CHARACTERISTICS:~* Karnofsky performance score 50-100%~* HIV negative~* Creatinine clearance ≥ 50 mL/min~* Not pregnant or nursing~* Negative pregnancy test~* Fertile patients must use effective contraception~PRIOR CONCURRENT THERAPY:~* No concurrent salicylates, nonsteroidal anti-inflammatory drugs, sulfonamides, or penicillins within the past week

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- methotrexate, leucovorin calcium, rituximab, and temozolomide (Type: EXPERIMENTAL): Determine the rate of toxicity, in terms of percentage of patients with grade 4 neurotoxicity, in patients with untreated primary CNS lymphoma treated with induction therapy comprising high-dose methotrexate, leucovorin calcium, rituximab, and temozolomide followed by consolidation therapy comprising cytarabine and etoposide phosphate.

Based on this trial design, predict the completion outcome and termination type (if applicable).